-The Hindu Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the country's actions "are not about access to medicine." In the case of Swiss drug-maker Novartis, whose cancer drug's patent protections were dismissed by the Supreme Court, the chamber has argued that...

-The Telegraph New Delhi: The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection. In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only...

-Down to Earth Advisory issued by health officials highlights complaints regarding excessive charges and delayed service To make private hospitals and nursing homes in Delhi more patient-friendly, the Aam Adami Party (AAP) government has issued a strict advisory to these establishments. It instructs all such establishments to display charges, compulsorily give primary aid in cases of emergency, and asks them to prescribe generic medicines. In the advisory issued on February 5, health officials...

-Down to Earth The free medicine scheme in Rajasthan may benefit Congress Of the many poll sops that Rajasthan Chief Minister Ashok Gehlot doled out in the past two years, the one scheme that seems to have struck the right chord with voters is the initiative to give free essential medicines at government healthcare facilities. The Mukhyamantri Nishulk Dava Yojna, launched in 2011, has offered some hope to the incumbent Congress government,...

-The Hindu Unless a deeper, institutional change is ushered in to break the nexus between drug companies and the regulatory regime, Indians consuming drugs may be exposing themselves to serious risks Even before I walked into the Mayflower Hotel in the heart of Washington on a crisp autumn afternoon to meet Dinesh Thakur, whistle-blower and former director of India-based pharmaceutical giant Ranbaxy, I had a hunch that this conversation would spark some...